Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
    SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- Medivation, Inc.
(Nasdaq: MDVN) today announced that data from an ongoing Phase 1-2 clinical
trial of its novel androgen receptor antagonist, MDV3100, will be presented
in an oral presentation at the 44th American Society of Clinical Oncology
(ASCO) Annual Meeting in Chicago.



    Session title: New Targeted Strategies for Patients with Prostate Cancer
    Session date and time: Monday, June 2 at 11:30 a.m. Central Time
    Abstract title: "Phase 1-2 Study of MDV3100 in Patients with Progressive
    Castration-Resistant Prostate Cancer (CRPC)" (Abstract #5006)
    To be presented by: Howard Scher, M.D., chief of the Genitourinary
    Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at
    Memorial Sloan-Kettering Cancer Center in New York, at approximately 12:15
    p.m. Central Time
    Location: W375e

    Dr. Scher's presentation will include data appearing in the abstract
posted today on the ASCO website, as well as additional study data not
reflected in the abstract.

    Medivation's ongoing Phase 1-2 trial of MDV3100 is an open-label
dose-escalation study enrolling prostate cancer patients who have failed
standard hormonal therapies. The study endpoints include safety,
tolerability, pharmacokinetics, effects on serum PSA levels and disease
progression. Medivation expects to complete the study and report final
top-line results in 2008.

    About Prostate Cancer

    Prostate cancer is the most common type of cancer, other than skin
cancer, and the second leading cause of cancer death in American men. More
than 1 million men in the United States have prostate cancer. An estimated
186,320 new cases are expected to be diagnosed in 2008, and approximately
28,660 men are expected to die this year from the disease(1). Patients with
castration-resistant (also known as hormone-refractory) prostate cancer
have few treatment options and a poor prognosis.

    About Medivation

    Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel small molecule drugs to treat serious diseases of the
central nervous system and cancers for which there are limited treatment
options. Medivation aims to revolutionize the treatment of these diseases
and offer hope to critically ill patients and their caregivers. The
Company's current clinical development program includes a pivotal and
confirmatory Phase 3 trial of Dimebon(TM) in Alzheimer's disease, a Phase 2
clinical trial of Dimebon in patients with mild-to-moderate Huntington's
disease, and a Phase 1-2 clinical trial of MDV3100 in patients with
castration-resistant (also known as hormone-refractory) prostate cancer.
For more information, please visit us at http://www.medivation.com.

    This press release contains forward-looking statements, including
statements regarding anticipated clinical and regulatory milestones, which
are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements involve risks and
uncertainties that could cause actual results to differ significantly from
those projected. You are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date of this
release. None of the Company's product candidates has been approved for
sale, significant additional animal and human testing is required in order
to seek marketing approval for any of its product candidates, and
Medivation cannot assure you that marketing approval can be obtained for
any of its product candidates. Furthermore, as is typically the case at
this stage of the regulatory review process, the FDA has not yet performed
an in-depth review of Medivation's preclinical and clinical data, so its
views remain subject to change. Medivation's filings with the Securities
and Exchange Commission, including its Annual Report on Form 10-KSB for the
year ended December 31, 2007 and its Quarterly Report on Form 10-Q for the
quarter ended March 31, 2008, include information about additional factors
that could affect the Company's financial and operating results.

    (1) American Cancer Society Web Site; Overview: Prostate Cancer

    (http://www.cancer.org/docroot/CRI/CRI_2_1x.asp?dt=36)
SOURCE Medivation, Inc.
http://www.medivation.com